Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depigoid birch pollen in allergic rhinoconjunctivitis: randomized double-blind placebo-controlled phase 3 trial
2004-001538-18Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Aug 2004
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic conjunctivitis (AC) and asthma comparing Depigoid birch pollen with Placebo (2 arms). Primary endpoint: Symptom load during predefined pollen season. Started Aug 2004; status: completed.
02
Drugs
depigoid birch
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)asthma
Beyond the preview
Go deeper on 2004-001538-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001538-18.